NEW FRONTIERS FOR THE CYTOSKELETAL PROTEIN LASP1

New Frontiers for the Cytoskeletal Protein LASP1

In the recent two decades, LIM and SH3 protein 1 (LASP1) has been developed from a simple actin-binding structural protein to a tumor biomarker and subsequently to a complex, nuclear transcriptional regulator.Starting with a brief historical perspective, this review will mainly compare and jolly rancher filled gummies contrast LASP1 and LASP2 from

read more

Semaglutide combined with empagliflozin vs. monotherapy for non-alcoholic fatty liver disease in type 2 diabetes: Study protocol for a randomized clinical trial.

BackgroundNonalcoholic fatty liver disease (NAFLD) is strongly associated with type 2 diabetes mellitus (T2DM).Lifestyle intervention remains a preferred treatment modality for NAFLD.The glucagon-like peptide (GLP-1) receptor agonists and sodium-glucose cotransporter-2 (SGLT-2) inhibitors have been developed as new glucose-lowering drugs, which can

read more